Treatment of Inflammatory Bowel Disease with Biologics
This book is a concise yet comprehensive overview of the use of biologics for the treatment of Crohn’s disease and ulcerative colitis. The volume details how best to utilize these medications in order to optimize their efficacy and safety, as well as how
- PDF / 4,794,738 Bytes
- 337 Pages / 439.43 x 683.15 pts Page_size
- 33 Downloads / 188 Views
Adam S. Cheifetz Joseph D. Feuerstein Editors
123
Treatment of Inflammatory Bowel Disease with Biologics
Adam S. Cheifetz • Joseph D. Feuerstein Editors
Treatment of Inflammatory Bowel Disease with Biologics
Editors Adam S. Cheifetz Beth Israel Deaconess Medical Center Center for Inflammatory Bowel Disease Harvard Medical School Boston, MA USA
Joseph D. Feuerstein Beth Israel Deaconess Medical Center Harvard Medical School Boston, MA USA
ISBN 978-3-319-60275-2 ISBN 978-3-319-60276-9 (eBook) https://doi.org/10.1007/978-3-319-60276-9 Library of Congress Control Number: 2017958966 © Springer International Publishing AG 2018 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Printed on acid-free paper This Springer imprint is published by Springer Nature The registered company is Springer International Publishing AG The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland
Preface
In the last number of years, the treatments for inflammatory bowel disease have been rapidly evolving. With the emergence of biologic therapies as the more effective medications for the treatment of moderate to severe ulcerative colitis and Crohn’s disease, understanding the best methods to effectively utilize them to induce and maintain remission is critical for the practicing gastroenterologist. In addition to antitumor necrosis (anti-TNF) agents (infliximab, adalimumab, golimumab, certolizumab) and anti-integrins (vedolizumab and natalizumab), the FDA has recently approved biosimilar anti-TNF agents and ustekinumab, an anti-IL12/ IL23 inhibitor. We are excited that this book, Treatment of Inflammatory Bowel Disease with Biologics, provides the reader with expert reviews on important topics pertaining to the use of biologics in inflammatory bowel disease as well their potential complications. The authors were carefully chosen for their expertise in the
Data Loading...
